Loading clinical trials...
Loading clinical trials...
An Open-Label, Dose Confirmation and Dosimetry Study of Interstitial 131 I-chTNT-1/B MAb (COTARA(TM)) For the Treatment of Glioblastoma Multiforme (GBM) at 1st or 2nd Relapse
Conditions
Interventions
iodine I 131 monoclonal antibody TNT-1/B
Locations
4
United States
Lurleen Wallace Comprehensive Cancer at University of Alabama-Birmingham
Birmingham, Alabama, United States
Winship Cancer Institute of Emory University
Atlanta, Georgia, United States
Wake Forest University Comprehensive Cancer Center
Winston-Salem, North Carolina, United States
Abramson Cancer Center of the University of Pennsylvania
Philadelphia, Pennsylvania, United States
Start Date
October 1, 2005
Completion Date
October 1, 2007
Last Updated
February 19, 2016
NCT00602667
NCT00683319
NCT07416188
NCT00897286
NCT06742593
NCT00884598
Lead Sponsor
Abramson Cancer Center at Penn Medicine
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions